Feature News

VIENNA, Va., Dec. 3 /PRNewswire-FirstCall/ -- In response to numerous shareholder inquiries, CEL-SCI Corporation (NYSE Alternext US: CVM) announced today that it has added updated pictures of it new manufacturing facility to its website. The pictures can be accessed through CEL-SCI's homepage (http://www.cel-sci.com) by clicking on the link "Updated Pictures of Manufacturing Facility" in the special highlights section.

CEL-SCI is developing its cancer product Multikine(R) for approval as a first line indication in head and neck cancer. The manufacturing facility was built to supply the upcoming and FDA cleared Phase III clinical trial, as well as commercial sale, of Multikine as a first line indication in treatment naive head and neck cancer patients. Head and neck cancer is one of the world's biggest cancers affecting about 650,000 people per annum worldwide.

CEL-SCI already has two partners who will participate in the Phase III trial: Teva Pharmaceuticals and Orient Europharma of Taiwan. Discussions with other potential partners are ongoing.

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, eliminate all of the tumor in 12% of the patients and to improve the patients' overall survival by 33% at a median of three and a half years following surgery.

CEL-SCI has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense. Most recently CEL-SCI announced that its newly discovered rheumatoid arthritis vaccine showed very promising results in animal tests.